{"id":62835,"date":"2026-03-24T01:02:24","date_gmt":"2026-03-24T00:02:24","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases\/"},"modified":"2026-03-24T01:02:24","modified_gmt":"2026-03-24T00:02:24","slug":"gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases\/","title":{"rendered":"Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases"},"content":{"rendered":"
\n

\n— Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead\u2019s Inflammation Portfolio —<\/i><\/p>\n

\n— Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines —<\/i><\/p>\n

FOSTER CITY, Calif.–(BUSINESS WIRE)–#GILD<\/a>–Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe acquisition adds OM336 (gamgertamig), a clinical\u2011stage BCMAxCD3 T cell engager, to Gilead\u2019s growing inflammation portfolio. OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course. In ongoing Phase 1\/2 clinical studies, OM336 has demonstrated transformative efficacy and a differentiated safety profile after a single treatment cycle in severe antibody-mediated orphan diseases including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). Gamgertamig has been granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of AIHA and ITP and is expected to enter registrational studies in 2027.<\/p>\n

\n\u201cThis acquisition underscores our commitment to advancing transformative therapies for people living with serious autoimmune diseases,\u201d said Dietmar Berger, MD, PhD, Chief Medical Officer of Gilead. \u201cBCMA is a validated target with emerging data demonstrating potentially transformative outcomes in autoimmune diseases. BCMA targeted T cell engagers represent a differentiated approach with the potential to induce durable disease control. This novel framework complements our expanding inflammation pipeline and reflects our strategy to invest in innovative science that may redefine standards of care.\u201d<\/p>\n

\nBCMA\u2011targeted T cell engagers are being investigated as a precision approach for severe inflammatory and autoimmune diseases by eliminating pathogenic B cells and plasma cells. By redirecting a patient\u2019s own T cells toward BCMA\u2011expressing plasma cells, clinical data suggests these agents may reduce inflammation, improve organ\u2011level disease, and, in some cases, enable an immune reset marked by durable, drug\u2011free remission without ongoing immunosuppression. T cell engagers represent an important modality for patients alongside Gilead\u2019s portfolio of CAR-T assets.<\/p>\n

\n\u201cFrom the outset, we saw the potential for gamgertamig to redefine the standard of care for immune-mediated diseases,\u201d said Jaideep Dudani, PhD, CoFounder and Chief Executive Officer of Ouro Medicines. \u201cSince then, we\u2019ve taken meaningful steps to advance that vision, with multiple trials now underway. With support from Gilead and Galapagos, we can build on the strong early foundation\u2014leveraging a proven track record in late stage development, launch, and commercialization to accelerate our programs and help deliver on the promise gamgertamig holds for patients with immune-mediated diseases, following our initial collaboration with Keymed Biosciences.\u201d<\/p>\n

\nTerms of the Transaction<\/span><\/b><\/p>\n

\nUnder the terms of the agreement Gilead will acquire all of the outstanding equity of Ouro Medicines for a total of $1,675 million in upfront cash consideration, subject to customary adjustments, which is payable at closing, and up to $500 million in contingent milestone payments. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions.<\/p>\n

\nStrategic Collaboration with Galapagos<\/span><\/b><\/p>\n

\nGilead is currently in advanced discussions with Galapagos with respect to a potential research and development collaboration on the acquired Ouro Medicines assets. The arrangement between Gilead and Galapagos is contemplated to include the following key terms:<\/p>\n